All studies
Not yet recruitingOBSERVATIONAL

Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

The TRANSHEMO 2 study is looking into how young adults (aged 20-29) with severe haemophilia manage their health as they grow up. Haemophilia is a rare blood condition that needs ongoing care. Moving from being a teenager to an adult can be tricky for anyone, but it's even more so for those with a long-term health condition. Researchers previously found that young adults sometimes find it harder to keep up with their treatment compared to teenagers. This new study wants to follow the same people over time to get a clearer picture. By understanding what helps or hinders young people in sticking to their treatment, doctors can offer better support during this important life stage. Participants will answer questionnaires to share their experiences.

At a glance

Status
Not yet recruiting
Sponsor
Assistance Publique Hopitaux De Marseille
Enrolment target
75
Start
01 Feb 2026
Estimated completion
01 Jun 2027

What is this study about?

Haemophilia is a rare genetic condition where your blood doesn't clot properly. In its severe form, it needs ongoing treatment to prevent serious problems. Thanks to modern medicine, people with haemophilia live much longer and healthier lives than in the past, but it means they manage a long-term health condition.

When teenagers grow into young adults, they go through many changes and gain more independence. For those with a health condition like haemophilia, this time can be even more complicated. They need to learn to take full responsibility for their health and treatment, moving away from their parents managing it all. If this transition doesn’t go smoothly, it might mean they struggle to keep up with treatment, which could affect their health and general well-being.

This study, called TRANSHEMO 2, is a follow-up to an earlier project. The first study found that young adults with severe haemophilia were less likely to stick to their treatment than teenagers. This new study wants to check in with the same people again, now that they are young adults. By looking at how things change over time, the researchers hope to understand more clearly what helps young people manage their haemophilia independently and successfully as they move into adulthood. This will help doctors and healthcare teams offer better support.

Key takeaways

  • This study follows young adults (20-29) with severe haemophilia.
  • It aims to understand how they manage their health after teenage years.
  • Participation involves answering questionnaires about your experiences.
  • No new medication or extra clinic visits are needed.
  • The findings could improve support for future young people with haemophilia.
  • You can stop participating at any time.

Who may be eligible?

This study is looking for young adults between 20 and 29 years old. To take part, you must have severe haemophilia (either type A or B). You also need to have been part of the original TRANSHEMO study when you were a teenager.

You should be registered with the FranceCoag registry, which is a record for people with bleeding disorders. Before joining, you'll receive a detailed information sheet about TRANSHEMO 2, and you must agree to take part.

However, if you have difficulty understanding information, or are unable to read or write, you won't be able to join. If you don't want to participate, that's absolutely fine, and you won't be included in the study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Are you between 20 and 29 years old?
  2. Do you have severe haemophilia (type A or B)?
  3. Did you take part in the original TRANSHEMO study when you were a teenager?
  4. Are you registered with the FranceCoag registry?
  5. Can you read and write without difficulty?
  6. Do you understand the information about the study and agree to participate?
Answer every question to see your result.

What does participation involve?

If you decide to take part in TRANSHEMO 2, your involvement will be quite straightforward. You will be asked to complete some questionnaires. These questionnaires will gather information about your experiences with managing your haemophilia, your lifestyle, and how you've been during your transition into young adulthood. There are no clinic visits or medication changes involved. The study will mainly involve providing your answers to these questions. The exact duration of your participation isn't specified, but it's likely a one-off set of questionnaires.

Potential risks and benefits

Taking part in this study is generally considered low-risk. The main thing you'll be doing is answering questionnaires, which shouldn't cause any physical harm. Some questions might make you think about your experiences, but you can choose not to answer anything you're uncomfortable with. The potential benefits are for future young people with haemophilia, as the study's findings could help improve support services during their transition to adulthood. You are free to withdraw from the study at any time without giving a reason, and this will not affect your medical care.

Locations (25)

  • CHU La Reunion
    Verified postcode
    Saint-Denis, France
  • CH Annecy - St Julien
    Verified postcode
    Annecy, France
  • Chu de Bordeaux
    Verified postcode
    Bordeaux, France
  • Chu de Caen
    Verified postcode
    Caen, France
  • Centre hospitalier Métropole Savoie
    Verified postcode
    Chambéry, France
  • CHU Clermont-Ferrand
    Verified postcode
    Clermont-Ferrand, France
  • Chu de Dijon
    Verified postcode
    Dijon, France
  • Chu de Grenoble
    Verified postcode
    Grenoble, France
  • CHRU de Lille
    Verified postcode
    Lille, France
  • CHU Limoges
    Verified postcode
    Limoges, France
  • Hospices Civils de Lyon
    Verified postcode
    Lyon, France
  • Assistance publique - Hôpitaux de Marseille
    Verified postcode
    Marseille, France

Common questions

What is the main goal of this study?

The main goal is to understand how young adults with severe haemophilia manage their health as they become independent, and what helps or makes it harder for them to stick to their treatment.

Will I have to take new medication or go to extra hospital appointments?

No, this study only involves answering questionnaires. You won't need to take any new medicines or attend extra appointments.

What is 'severe haemophilia'?

Severe haemophilia is the most serious type of haemophilia, where the blood clotting factor is very low, meaning you need regular treatment to prevent bleeding problems.

What if I change my mind about taking part?

You can decide to stop participating at any time without giving a reason, and it will not affect your medical care.

What does 'adherence to healthcare' mean?

Adherence to healthcare means how well a person follows the advice and treatment plan given by their doctors or healthcare team.

How to find out more

Noémie Resseguier, MD

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "Determinants and Consequences of the Transition to Adulthood…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.